Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines
BACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines.METHODS: Patients on BPaL under operational research, or 9–11-mont...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-06-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000006/art00002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|